SM08502-Mediated β-Catenin Repression Synergizes with Olaparib to Inhibit Tumor Progression

View Full Paper

Ask AI

Bookmark

Authors

Discussion

Preclinical analysis shows synergy of SM08502 and Olaparib reduces tumor progression and alters gene expression in PARP inhibitor-resistant HGSC.

Significantly reduces tumor progression in models of PARP inhibitor-resistant high-grade serous carcinoma.
The combination of SM08502 and Olaparib alters gene expression and reduces tumor growth.
Assessment using immune-competent and immune-compromised models confirms the effectiveness of the drug combination.
Combination treatment may improve options for patients facing PARP inhibitor resistance in HGSC.

Corr et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Preclinical analysis shows synergy of SM08502 and Olaparib reduces tumor progression and alters gene expression in PARP inhibitor-resistant HGSC.